In the firm's investment criteria and process, they are informed by a Stanford-born methodology of health technology innovation known as Biodesign.

Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology.The focal point lies in supporting founders who possess a deep comprehension of the intricate network of healthcare system stakeholders, coupled with significant engineering innovation, advanced data science, and information technology-enabled solutions.

Operating primarily from Europe, the firm aim is to identify and assist founders driven by genuine needs, committed to serving these stakeholders on a global scale with effectiveness and efficiency.The firm invests broadly across Europe, including the United Kingdom, in the United States, Canada, Israel, and Australia, with a collaborative approach in how they work and interact with other players in their industry.

Their goal is to help thoughtful and committed teams bridge the chasm from founding to series A capital and access global markets.